The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate of trastuzumab [a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)] and DM1 (an inhibitor of tubulin polymerisation). It was initially approved in the European Union for the treatment of adult patients with HER2-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, J., Vleminckx, C., Sarac, S., Sosa, A., Bergh, J., Giuliani, R., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920831/
https://www.ncbi.nlm.nih.gov/pubmed/33647599
http://dx.doi.org/10.1016/j.esmoop.2021.100074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920831/
https://www.ncbi.nlm.nih.gov/pubmed/33647599
http://dx.doi.org/10.1016/j.esmoop.2021.100074

Ejemplares similares